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LETTER TO THE EDITOR
Oncogenic activation of MPL/thrombopoietin receptor by 17
mutations at W515: implications for myeloproliferative
neoplasms
Leukemia advance online publication, 23 October 2015;
doi:10.1038/leu.2015.271
Philadelphia negative myeloproliferative neoplasms (MPNs)
include polycythemia vera, essential thrombocythemia (ET) and
primary myeloﬁbrosis (PMF). Those MPNs are clonal diseases for
which the phenotype is almost driven by exon-speciﬁc somatic
mutations in three genes: JAK2 exon14, MPL exon10 and
CALR exon9.
MPNs lacking those speciﬁc driver mutations are commonly
called ‘triple negatives’, which amount to 15% of ET and PMF and
appear to share with phenotypic drivers the ability to activate the
JAK/STAT pathway.1 Beside JAK2 and STATs, MPL/TpoR is a central
player in the pathogenesis of MPN being essential for developing
a full JAK2 V617F disease in mice.2 However, the receptor itself can
suffer from pathological activating mutations within exon10.
Exon10 covers roughly the transmembrane domain (TMD) of TpoR
and starts at Trp491 (exoplasmic TMD boundary) to end shortly
after Trp515 (cytosolic TMD boundary). Those two tryptophans are
predicted to be on the same face of the TMD helix and are
capping the TMD helix in the membrane bilayer. Trp515 is found
in an amphipathic and helical motif ‘RWQFP’ that prevents
activation of TpoR.3 Trp515 itself controls dimerization and
activation of the receptor.4 W515S,5 W515L,6 W515K,7 W515A,8
W515R9 and W515G10 were shown to be present in a subset of
MPN patients (nearby 4% ET and 8% PMF in large cohorts), or in
autonomous cell lines but have never been found in polycythemia
vera or other myeloid diseases.7,11,12 W515L/K mutations are the
most prevalent mutations that activate the receptor and
recapitulate an ET/PMF phenotype with marked thrombocytosis
in murine bone marrow transplant assays.6,8 Besides missense
mutations, rare deletions and insertions around W515 are found in
MPN patients.10,12
Our goals were: (i) to identify other MPL mutations that should
be tested in MPN patients by mutation-speciﬁc PCR; and (ii) to
determine the amino acid requirements at position 515 to prevent
TpoR self-activation.
To these ends, cDNAs coding for HA-TpoR and HA-TpoR
mutants were cloned in pMX-IRES-green ﬂuorescent protein
(GFP) (for cell line expression) and pMEGIX-IRES-GFP (for bone
marrow reconstitution experiments). Vectors were mutated using
the QuickChange Site-Directed Mutagenesis Kit (Agilent Technol-
ogies, Santa Clara, CA, USA), digested with Dpn-I (NEB) and then
used to transform E Coli competent cells. TpoR mutant plasmids
were puriﬁed for this study using Qiagen kits before being fully
sequenced (Qiagen N.V., Venlo, Netherlands). Afterwards, STAT5
transcriptional activity was assessed at 24 h posttransfection by
measuring ﬁreﬂy luciferase production in cells transiently trans-
fected using lipofectamine 2000 (Thermo Fisher Scientiﬁc,
Waltham, MA, USA) by the PGRR5 STATs responsive reporter,
JAK2, STAT5 and a pRL-TK internal control. Luciferase ratio were
obtained from sequential reads acquire on a Viktor X (Perkin
Elmer, Waltham, MA, USA) using DLR reagents (Promega, Madison,
WI, USA). Then, to obtain Ba/F3 cell lines stably expressing the
TpoR or W515 mutants, retrovirus were produced as described.3
Infected cells were sorted by ﬂuorescence-activated cell sorting
for equivalent GFP levels. The cell proliferation of BaF3 murine pro
B cells was measured using a CellTiter-Glo luminescent cell
viability assay (Promega). This ATP-based assay was carried
out according to the manufacturer’s protocol. Cells were ﬁrst
retrovirally infected with virus and plated at 5000 cells/well in
RPMI 1640 (Thermo Fisher Scientiﬁc)-containing 10% fetal bovine
serum for 72 h. Light emission was read with a Viktor X (Perkin
Elmer). IL-3 served as an internal control for growth efﬁciency. For
mouse bone marrow transplantation, 106 total bone marrow
cells retrovirally tranduced with a pMEGIX-TpoR W515C-IRES-GFP
retrovirus were injected into 8-weeks-old lethally irradiated C57BL/
6 mice as described.8 Mice were assessed for GFP expression at
day 45 and blood was analyzed using a Melet Schloessing MS9-3
cell counter (Melet Schloesing Laboratoires, Osny, France).
In this study, we identify 17 active mutants resulting from
substitutions at the Trp515 position. We performed saturation
mutagenesis of TpoR Trp515 by mutating position 515 of the full
length TpoR to all other 19 amino acids and tested their activity in
transcriptional and proliferation assays. Our results show that all
polar, charged or hydrophobic residues placed at position W515
activate the TpoR/ JAK2/STAT5 transcriptional cascade in absence
of ligand. As previously described,4 the most conservative
aromatic residues show a weaker but signiﬁcant increase in basal
activity conﬁrming the key role of tryptophan at that position. In
our hands, only two residues out of 17, namely cysteine (W515C)
and proline (W515P) were able to keep the receptor inactive in the
absence of Tpo. Although the TpoR W515P mutant shows a defect
in responding to Tpo stimulation, W515C can be considered as a
fully competent receptor when stimulated by Tpo (Figure 1a, left
panel). W515-F517del, where three residues are deleted in the
RWQFP motif leads to a ‘-RXXXPHAY-’ motif with a W515P change.
This mutant is inactive in the absence of Tpo (Figure 1a, right
panel) like the TpoR W515P mutant. In contrast, W515-P518del,
where four residues are deleted from the motif leads to
‘-RXXXXAHAY-’ sequence. This mutant is active, with a W515A
substitution, like the TpoR W515A mutant (Figure 1a, right panel).
Of interest, rare MPN indel TpoR mutants W515-P518delinsAAAA
and L513insCTGCTGAGCTGC contains at W515 a lysine or a serine,
respectively.12 Our mutagenesis explains why these mutants are
pathogenic as both W515K and W515S are active mutants.
Ba/F3 cells stably expressing the W515C mutant show neither a
constitutive growth nor cytokine hypersensitivity (Figure 1b). The
growth pattern perfectly matches the one of TpoR wild-type. This
is in contrast with the autonomous growth induces by TpoR
W515K or by another TMD mutant (S505N) found mainly in
familial form of ET.13
The W515P also does not allow autonomous Ba/F3 growth,
while supporting a full Tpo response (Figure 1c, upper panel). Cell
surface localization analysis revealed a mild cell-surface localiza-
tion defect of W515P, despite a higher level of transcription as
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measured by GFP (Figure 1c, bottom panel). We used bone
marrow reconstitution as a stringent test for TpoR W515C activity.
Transduction of the TpoR W515C mutant in bone marrow cells and
reconstitution were very efﬁcient with near 100% GFP positive
cells for each of six mice. Blood counts obtained at day 45 were
similar to reference value of normal C57BL/6 with a mean of 8900
WBC/μl, 15.6 g/dl of hemoglobin and a 1 100 000 platelets/μl
(Figure 1d). Thus, this mutant is not pathogenic, when we
compare with other mutants, like TpoR S505N (not shown) or with
TpoR W515L/A mutants.6,8
Our data emphasize that seventeen mutations at W515 are
potentially oncogenic but only six point mutations have been
described to date at this residue in patients. Thus, 11 more
mutants could be found in patients, and also deletions or
insertions that would place such 11 residues at W515 are
predicted to induce oncogenic activation. We showed that
tryptophan, cysteine and proline are the only residues maintaining
the un-liganded TpoR inactive. W515P prevents full receptor
activity probably by disrupting or kinking the helix and interfering
with membrane insertion and trafﬁc to the surface. Unlike proline,
glycine activates at W515, and glycines are known to be tolerated
and mediate interfacial contacts between membrane helices.
Surprisingly, cysteine does not activate at W515. Cysteine residues
are rare in TM proteins. An exception is found in the cysteine-rich
transmembrane (CYSTM) protein family that could protect the
membrane from oxygen radical species.14 It is puzzling that
W515A and W515S are active, but W515C is inactive, as these
residues all have roughly the same volume. Ser and Cys are both
capable of hydrogen bonding. Part of the answer could come
from a 1968 paper from Heitmann15 demonstrating an unex-
pected hydrophobic nature of the cysteine side chain. Interest-
ingly, a cysteine is found at the equivalent W515 position as in
birds (RCTFP motif) or in turtle (RCSFP motif), further supporting
the notion that cysteine does not activate TpoR. To validate that
Figure 1. Site-speciﬁc W515 saturation mutagenesis (a) (left ) 17 out of 20 mutations of the TpoR W515 induce constitutive signaling via JAK2
and STAT5. (Right) additional TpoR deletions in the RWQFP juxtamembrane motif ( RXXXP or deletion of 3 residues) and ( RXXXX or deletion of
4 residues) were tested to mimic W515P or W515A, respectively. The indicated TpoR W515 mutants were expressed in γ-2 A cells cotransfected
with JAK2 and tested for Tpo-dependent and -independent induction of STAT5-dependent transcriptional activity. A ﬁreﬂy luciferase reporter
(FF), which responds to JAK/STAT1,3,5 pathways was coexpressed with a renilla (RL) luciferase control reporter driven by a constitutive
promoter. The luciferase ratio (FF/RL) was used to reduce variability due to cell viability and transfection efﬁciency. Shown are normalized
averages of at least nine replicates± s.e.m. from three separate experiments. NS, nonsigniﬁcant; *P⩽ 0.05; **P⩽ 0.01;***P⩽ 0.001, JMP Pro 11
(SAS Institute, Cary, NC, USA) nonparametric multiple comparison test, Steel test with control. (b) Cell proliferation of Ba/F3 cells stably
expressing TpoR WT, W515C, W515K and S505N at equivalent expression levels. Proliferation was assessed by CellTiterGlo ATP-based assay
(Promega, Sunnyvale, CA, USA) in absence and presence of Tpo. IL-3 in green served as an internal control for growth. (c) The TpoR W515P
mutant was assayed for cell viability (upper). Cell surface localization of HA-tagged TpoR W515P was measured by ﬂow cytometry (lower). (d)
Blood parameters were obtained at day 45 by retro-orbital bleeding of six lethally irradiated C57BL/6 mice reconstituted at an average of 96%
with the murine TpoR W508C mutant, which is the murine homolog of the human TpoR W515C mutant. Green box represent reference
ranges for C57Bl/6 mice.
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TpoR W515C is not active we used retroviral expression in bone
marrow of the murine TpoR W508C and adoptive transplantation.
Bone marrow showed a mild increase in cellularity with
persistence of adipocytes and without any megakaryocyte
hyperplasia or sign of MPN. Mice were sacriﬁced after 4 month
without any evidence of diseases.
This study reports that 17 substitutions at W515 lead to
constitutive activation of TpoR. Also, certain delins around W515
that place activating residues at W515 lead to active receptors. We
also show that cysteine and proline are the only residues besides
tryptophan that do not activate TpoR at position W515. As
commercial kits are now only focused on W515K/L and as we are
in the beginning of the sequencing era, the region around W515
should be extensively explored in MPN patients.
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